Early use of inhaled corticosteroids in the emergency department treatment of acute asthmaSee related handout on how to treat an asthma attackwritten by corticosteroids acute asthma authors of this article. Asthma exacerbations can be classified as mild, moderate, severe, or life threatening. Criteria for exacerbation severity are based corticosteroidx symptoms and physical examination parameters, as well as lung function and oxygen saturation. In patients with a peak expiratory flow of 50 to 79 percent of their personal best, up to two treatments of two to six inhalations of short-acting beta 2 agonists 20 minutes apart followed by a reassessment of peak expiratory flow and symptoms may be safely employed at home. Corticosterolds using a hand-held metered-dose inhaler with a spacer device is at dbol gains pics equivalent to nebulized beta 2 agonist therapy in children and adults. In the ambulatory and emergency department settings, the goals of treatment are correction of severe hypoxemia, rapid reversal of airflow obstruction, and reduction of the risk of relapse. Multiple doses of inhaled anticholinergic medication combined with beta 2 agonists corticosteroids acute asthma lung function and corticosteroids acute asthma hospitalization in school-age children with severe asthma exacerbations.
Medscape Log In
Asthma is one of the most common chronic diseases in the world. It is estimated that million people of all ages, and all ethnic backgrounds, suffer from asthma, with 1 in every deaths worldwide attributed to asthma. In an asthma attack, the airways passages to the lungs narrow from muscle spasm and swelling inflammation.
Corticosteroid drugs can be used to reduce the swelling. Corticosteroids can be inhaled, or taken systemically by mouth orally or through a drip into the veins intravenously. Standard treatment for asthma attacks is to administer beta 2 -agonists to open up the airways and systemic corticosteroids to reduce the inflammation.
The purpose of this review was to determine if the use of inhaled corticosteroid ICS agents is beneficial in emergency department treatment settings. A total of 90 studies were identified for this review ; 20 were deemed relevant and selected for inclusion 13 paediatric , 7 adult , with a total number of patients.
This review found that inhaled corticosteroids used alone or in combination with systemic corticosteroids helped to relieve asthma attacks, were well tolerated and had few side effects. However, the most effective drug and dosage are unclear. The studies in the review included a variety of ICSmedications: The review also found that ICS administered in this setting resulted in fewer hospital admissions. There was a reduction from 32 to 17 hospital admissions per hundred patients treated with ICS agents compared with placebo.
At this time there is insufficient evidence to support using ICS agents alone as a replacement for systemic corticosteroid therapy in acute asthma attacks. However, there are many unanswered questions about the use of ICS in the emergency department treatment setting.
Future research should focus on optimal dosage, dosage frequency and delivery device, identification of effective ICS agents, clearly defined outcomes such as admissions criteria, pulmonary function testing and follow-up after discharge from emergency departments.
ICS therapy reduces hospital admissions in patients with acute asthma who are not treated with oral or intravenous corticosteroids. They may also reduce admissions when they are used in addition to systemic corticosteroids; however, the most recent evidence is conflicting. There is insufficient evidence that ICS therapy results in clinically important changes in pulmonary function or clinical scores when used in acute asthma in addition to systemic corticosteroids.
Also, there is insufficient evidence that ICS therapy can be used in place of systemic corticosteroid therapy when treating acute asthma. Further research is needed to clarify the most appropriate drug dosage and delivery device, and to define which patients are most likely to benefit from ICS therapy. Use of similar measures and reporting methods of lung function, and a common, validated, clinical score would be helpful in future versions of this meta-analysis.
Systemic corticosteroid therapy is central to the management of acute asthma. The use of inhaled corticosteroids ICS may also be beneficial in this setting. To determine the benefit of ICS for the treatment of patients with acute asthma managed in the emergency department ED. We identified controlled clinical trials from the Cochrane Airways Group specialised register of controlled trials. Bibliographies from included studies, known reviews, and texts also were searched. The latest search was September Studies were included if patients presented to the ED or its equivalent with acute asthma, and were treated with ICS or placebo , in addition to standard therapy.
Two review authors independently selected potentially relevant articles, and then independently selected articles for inclusion. Methodological quality was independently assessed by two review authors. There were three different types of studies that were included in this review: For the analysis , the first two types of studies were included as separate subgroups in the primary analysis ICS vs.
Data were extracted independently by two review authors if the authors were unable to verify the validity of extracted information. Missing data were obtained from the authors or calculated from other data presented in the paper. The primary analysis employed a fixed-effect model and a random-effects model was used for sensitivity analysis. Heterogeneity is reported using I-squared I 2 statistics. Twenty trials were selected for inclusion in the primary analysis 13 paediatric , seven adult , with a total number of patients.
This represents a reduction from 32 to 17 hospital admissions per patients treated with ICS in comparison with placebo. Subgroup analysis of hospital admissions based on concomitant systemic corticosteroid use revealed that both subgroups indicated benefit from ICS in reducing hospital admissions ICS and systemic corticosteroid versus systemic corticosteroid: Only a small number of studies reported these outcomes such that they could be included in the meta-analysis and most of the studies in this comparison did not administer systemic corticosteroids to either treatment group.
There was no evidence of significant adverse effects from ICS treatment with regard to tremor or nausea and vomiting. In the secondary analysis of studies comparing ICS alone versus systemic corticosteroid alone, heterogeneity among the studies complicated pooling of data or drawing reliable conclusions.
Early use of inhaled corticosteroids in the emergency department treatment of acute asthma Asthma is one of the most common chronic diseases in the world. At this time there is insufficient evidence to support using ICS agents alone as a replacement for systemic corticosteroid therapy in acute asthma attacks However, there are many unanswered questions about the use of ICS in the emergency department treatment setting.
Data collection and analysis: You may also be interested in: Inhaled corticosteroids for acute asthma following emergency department discharge Early emergency department treatment of acute asthma with systemic corticosteroids Does adding antileukotriene agents to usual care when people are suffering an asthma attack in the emergency department help?
Combined beta-agonists and anticholinergics compared to beta-agonists alone for adults with asthma treated in emergency departments Magnesium sulfate for treating exacerbations of acute asthma in the emergency department.